Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Claya vs Tell Her Doc

Claya
Graded #264

Higher grade

vs+5.399999999999999
Tell Her Doc
Graded #400

Lower grade

The verdict

Claya takes it — 62.8/100 to 57.4/100.

Claya grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Claya is a direct-to-consumer telehealth platform offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueClaya +14
42
28
Dose & formulationClaya +12
75
63
Clinical oversightClaya +6
82
76
Labs & monitoringClaya +1
53
52
FulfillmentTell Her Doc +16
67
83
Contract termsEven
61
61
Claya · left barTell Her Doc · right bar

The numbers

MetricClayaTell Her Doc
WeighScore62.8/10057.4/100
GradeCC
Scorecard rank#264#400
Semaglutide$299/mo (compounded)$269/mo (microdose tier, plus a separate fee, compounded)
Tirzepatide$299/mo (compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
Claya

Graded #264 · C

Strengths

  • Two named licensed clinicians (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1
  • Two named pharmacy partners with full addresses (RedRock, UT and Healthware, KY)
  • Both injectable and oral-tablet forms offered for semaglutide and tirzepatide
  • Weight-loss money-back guarantee published on the homepage
  • Free expedited shipping included in the monthly price

Where it loses points

  • States-served list not disclosed — you must check at checkout
  • LegitScript certification status not displayed
  • Corporate legal entity not disclosed on the site or privacy policy
  • Oral compounded tablets have weaker efficacy data than injectable semaglutide
  • Intro pricing is higher at refill ($299), erasing the first-month advantage
Tell Her Doc

Graded #400 · C

Strengths

  • Full compounded GLP-1 lineup — semaglutide and tirzepatide in injection, oral and orally-dissolving-tablet forms, plus microdoses
  • Names its compounding pharmacy partner (Casa Pharma RX), which is independently listed in our pharmacy registry
  • No monthly membership, cancel anytime, free discreet shipping; HSA/FSA eligible with buy-now-pay-later plans
  • Serves patients in all 50 states via a private online consultation

Where it loses points

  • 'All sales are final' — no refunds once medication has left the pharmacy
  • Exact price is plan-dependent, shown after you pick a product; advertised 'starting at $269', with a lower $140 intro on oral semaglutide
  • References LegitScript but without an independently verifiable seal — we couldn't confirm certification
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard